Patents by Inventor Mathilde DUSSEAUX

Mathilde DUSSEAUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD70
    Publication number: 20230041456
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Application
    Filed: June 17, 2022
    Publication date: February 9, 2023
    Inventors: Surabhi SRIVATSA SRINIVASAN, Niranjana NAGARAJAN, Siler PANOWSKI, Yoon PARK, Tao SAI, Barbra SASU, Thomas VAN BLARCOM, Mathilde DUSSEAUX, Roman GALETTO
  • Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
    Patent number: 10709775
    Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: July 14, 2020
    Assignee: Cellectis
    Inventor: Mathilde Dusseaux
  • CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING CD38 ANTIGEN AND FOR CD38 GENE INACTIVATION
    Publication number: 20180236053
    Abstract: Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 23, 2018
    Inventor: Mathilde DUSSEAUX